statistiche ricercatore

Continente	#
NA - Nord America	540
EU - Europa	526
AS - Asia	343
SA - Sud America	54
Continente sconosciuto - Info sul continente non disponibili	14
AF - Africa	12
Totale	1.489

Nazione	#
US - Stati Uniti d'America	511
RU - Federazione Russa	266
SG - Singapore	138
IT - Italia	68
CN - Cina	63
DE - Germania	44
VN - Vietnam	43
BR - Brasile	38
HK - Hong Kong	37
PL - Polonia	32
CA - Canada	19
FR - Francia	18
GB - Regno Unito	18
SE - Svezia	17
IE - Irlanda	16
IN - India	15
FI - Finlandia	14
BD - Bangladesh	11
NL - Olanda	11
KR - Corea	10
JP - Giappone	9
ID - Indonesia	6
VE - Venezuela	6
CZ - Repubblica Ceca	5
CH - Svizzera	3
CO - Colombia	3
EC - Ecuador	3
MX - Messico	3
NG - Nigeria	3
ZA - Sudafrica	3
AR - Argentina	2
AT - Austria	2
BE - Belgio	2
BJ - Benin	2
ES - Italia	2
JM - Giamaica	2
LT - Lituania	2
PK - Pakistan	2
TG - Togo	2
UA - Ucraina	2
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
BS - Bahamas	1
CL - Cile	1
CR - Costa Rica	1
DK - Danimarca	1
DO - Repubblica Dominicana	1
DZ - Algeria	1
HN - Honduras	1
IL - Israele	1
IQ - Iraq	1
IR - Iran	1
LA - Repubblica Popolare Democratica del Laos	1
LB - Libano	1
MA - Marocco	1
NI - Nicaragua	1
NP - Nepal	1
PT - Portogallo	1
RS - Serbia	1
TR - Turchia	1
UY - Uruguay	1
UZ - Uzbekistan	1
Totale	1.475

Nome	#
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic	192
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer	169
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program	167
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done	165
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned	163
Infections and Immunotherapy in Lung Cancer: A Bad Relationship?	158
Genetic and non-genetic resistance mechanisms in non-small cell lung cancer harboring (non-ALK) oncogenic fusions	134
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study	120
Body composition as a modulator of response to immunotherapy in lung cancer: time to deal with it	117
Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumab	91
Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity	13
Totale	1.489

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	64	0	7	0	2	3	2	0	2	2	1	11	34
2022/2023	106	4	12	9	25	4	29	0	4	14	0	3	2
2023/2024	78	4	3	4	9	5	10	12	8	7	2	9	5
2024/2025	266	12	8	9	51	5	13	5	12	34	17	35	65
2025/2026	930	48	61	86	168	242	46	68	35	70	61	29	16
2026/2027	19	14	5	0	0	0	0	0	0	0	0	0	0
Totale													1.489

CATALOGO DEI PRODOTTI DELLA RICERCA